{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:06:23Z","timestamp":1782389183512,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","award":["20758"],"award-info":[{"award-number":["20758"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12376183"],"award-info":[{"award-number":["PNRR-MAD-2022-12376183"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["ECS00000017"],"award-info":[{"award-number":["ECS00000017"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bioorg.2025.109260","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:09:47Z","timestamp":1763629787000},"page":"109260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["ProTide-enabled antibody-drug conjugates: A novel platform for the targeted delivery of phosphorylated drugs"],"prefix":"10.1016","volume":"167","author":[{"given":"Sofia","family":"Siciliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clizia","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Finetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elva","family":"Morretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Petricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Poggialini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Trabalzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Vinciarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetra","family":"Zambardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.bioorg.2025.109260_bb0005","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1021\/cr5002035","article-title":"Synthesis of nucleoside phosphate and phosphonate prodrugs","volume":"114","author":"Pradere","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2025.109260_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100063","article-title":"Development and clinical application of phosphorus-containing drugs","volume":"8","author":"Yu","year":"2020","journal-title":"Med. Drug Discov."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109260_bb0015","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50\u00a0years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"issue":"23","key":"10.1016\/j.bioorg.2025.109260_bb0020","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1021\/acs.chemrev.6b00209","article-title":"Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs","volume":"116","author":"Shelton","year":"2016","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109260_bb0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbrc.2012.03.122","article-title":"DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells","volume":"421","author":"Saiki","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109260_bb0030","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1021\/jacs.1c09574","article-title":"Aptamers entirely built from therapeutic nucleoside analogues for targeted cancer therapy","volume":"144","author":"Zhu","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109260_bb0035","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2147\/IJN.S231144","article-title":"Enhancing antitumor efficacy of nucleoside analog 5-fluorodeoxyuridine on her2-overexpressing breast cancer by affibody-engineered DNA nanoparticle","volume":"15","author":"Zhang","year":"2020","journal-title":"Int. J. Nanomedicine"},{"issue":"34","key":"10.1016\/j.bioorg.2025.109260_bb0040","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1002\/anie.201603488","article-title":"Integrin-targeting knottin peptide\u2013drug conjugates are potent inhibitors of tumor cell proliferation","volume":"55","author":"Cox","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"issue":"98","key":"10.1016\/j.bioorg.2025.109260_bb0045","doi-asserted-by":"crossref","first-page":"17435","DOI":"10.1039\/C5CC06654A","article-title":"The rational design of a gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells","volume":"51","author":"Han","year":"2015","journal-title":"Chem. Commun."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109260_bb0050","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/cmdc.200900289","article-title":"Aryloxy phosphoramidate triesters: A technology for delivering monophosphorylated nucleosides and sugars into cells","volume":"4","author":"Mehellou","year":"2009","journal-title":"Chem. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109260_bb0055","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","article-title":"The ProTide prodrug technology: From the concept to the clinic","volume":"61","author":"Mehellou","year":"2018","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109260_bb0060","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cmdc.201600156","article-title":"The ProTides boom","volume":"11","author":"Mehellou","year":"2016","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109260_bb0065","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/ejoc.201800158","article-title":"Stereoselective synthesis of sofosbuvir through nucleoside phosphorylation controlled by kinetic resolution","author":"Cini","year":"2018","journal-title":"Eur. J. Org. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109260_bb0070","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/phar.2174","article-title":"Tenofovir alafenamide for the treatment of chronic hepatitis B monoinfection","volume":"38","author":"Childs-Kean","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"10236","key":"10.1016\/j.bioorg.2025.109260_bb0075","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109260_bb0080","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acsmedchemlett.8b00586","article-title":"The ProTide prodrug technology: Where next?","volume":"10","author":"Alanazi","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109260_bb0085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nchem.2415","article-title":"Recent advances in the construction of antibody\u2013drug conjugates","volume":"8","author":"Chudasama","year":"2016","journal-title":"Nat. Chem."},{"issue":"26","key":"10.1016\/j.bioorg.2025.109260_bb0090","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1002\/anie.201500088","article-title":"Self-immolative spacers: kinetic aspects, structure\u2013property relationships, and applications","volume":"54","author":"Alouane","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109260_bb0095","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioorg.2025.109260_bb0100","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1039\/B404946B","article-title":"Self-immolative dendrimer biodegradability by multi-enzymatic triggering","volume":"14","author":"Amir","year":"2004","journal-title":"Chem. Commun."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109260_bb0105","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.xphs.2020.08.014","article-title":"Perspectives about self-immolative drug delivery systems","volume":"109","author":"Gonzaga","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109260_bb0110","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/bc0600214","article-title":"Development and properties of \u03b2-glucuronide linkers for monoclonal antibody\u2212drug conjugates","volume":"17","author":"Jeffrey","year":"2006","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109260_bb0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1021\/ml100039h","article-title":"Expanded utility of the \u03b2-glucuronide linker: ADCs that deliver phenolic cytotoxic agents","volume":"1","author":"Jeffrey","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109260_bb0120","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ejmech.2017.08.008","article-title":"Development and evaluation of \u03b2-galactosidase-sensitive antibody-drug conjugates","volume":"142","author":"Kolodych","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"31","key":"10.1016\/j.bioorg.2025.109260_bb0125","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1039\/C7SC05266A","article-title":"Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation","volume":"9","author":"Cini","year":"2018","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2025.109260_bb0130","first-page":"9","article-title":"ErbB2 targeted epigenetic modulation: Anti-tumor efficacy of the ADC trastuzumab-HDACi ST8176AA1","author":"Milazzo","year":"2020","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109260_bb0135","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1039\/D0CC06131J","article-title":"Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition","volume":"57","author":"Cianferotti","year":"2021","journal-title":"Chem. Commun."},{"issue":"75","key":"10.1016\/j.bioorg.2025.109260_bb0140","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.1039\/D2CC03052G","article-title":"A PH-responsive crosslinker platform for antibody-drug conjugate (ADC) targeting delivery","volume":"58","author":"Migliorini","year":"2022","journal-title":"Chem. Commun."},{"issue":"41","key":"10.1016\/j.bioorg.2025.109260_bb0145","article-title":"DFT-guided discovery of ethynyl-triazolyl-phosphinates as modular electrophiles for chemoselective cysteine bioconjugation and profiling","volume":"61","author":"Stieger","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109260_bb0150","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/jacs.5b12547","article-title":"Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody\u2013drug conjugates","volume":"138","author":"Kern","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109260_bb0155","article-title":"Expanding the payload scope in antibody-drug conjugates: Unprecedented delivery of hydroxy-containing drugs through self-immolative phosphoramidates","author":"Kasper","year":"2025","journal-title":"Research Square"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109260_bb0160","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2174\/092986712799320682","article-title":"Gemcitabine: A critical nucleoside for cancer therapy","volume":"19","author":"Gesto","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109260_bb0165","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/jm401853a","article-title":"Application of ProTide technology to gemcitabine: A successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development","volume":"57","author":"Slusarczyk","year":"2014","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109260_bb0170","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1021\/acs.biomac.9b01493","article-title":"Acid-triggered release of native gemcitabine conjugated in polyketal nanoparticles for enhanced anticancer therapy","volume":"21","author":"Zhong","year":"2020","journal-title":"Biomacromolecules"},{"issue":"3","key":"10.1016\/j.bioorg.2025.109260_bb0175","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/genes13030466","article-title":"Recent development of prodrugs of gemcitabine","volume":"13","author":"Pandit","year":"2022","journal-title":"Genes (Basel)"},{"issue":"30","key":"10.1016\/j.bioorg.2025.109260_bb0180","doi-asserted-by":"crossref","first-page":"17480","DOI":"10.1039\/D5NR02005K","article-title":"Recent progress in gemcitabine-loaded nanoparticles for pancreatic cancer therapy: A review","volume":"17","author":"Li","year":"2025","journal-title":"Nanoscale"},{"issue":"23","key":"10.1016\/j.bioorg.2025.109260_bb0185","doi-asserted-by":"crossref","first-page":"10400","DOI":"10.1021\/acs.jmedchem.6b00523","article-title":"Nucleoside phosphate and phosphonate prodrug clinical candidates","volume":"59","author":"Thornton","year":"2016","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.109260_bb0190","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2-D-2\u2032-Deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2025.109260_bb0195","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1021\/jm900447q","article-title":"Phosphoramidate prodrugs of 2\u2032-C-methylcytidine for therapy of hepatitis C virus infection","volume":"52","author":"Gardelli","year":"2009","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109260_bb0200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1091-255X(01)80025-1","article-title":"Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)","volume":"5","author":"B\u00fcchler","year":"2001","journal-title":"J. Gastrointest. Surg."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109260_bb0205","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.3390\/cimb46030171","article-title":"Unveiling the molecular mechanism of trastuzumab resistance in SKBR3 and BT474 cell lines for HER2 positive breast cancer","volume":"46","author":"Kokot","year":"2024","journal-title":"Curr. Issues Mol. Biol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682501140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682501140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T03:43:30Z","timestamp":1766115810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682501140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"alternative-id":["S004520682501140X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109260","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ProTide-enabled antibody-drug conjugates: A novel platform for the targeted delivery of phosphorylated drugs","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109260"}}